Back to top

Praxis Precision granted breakthrough therapy designation for elsunersen

Praxis Precision (PRAX) announced that the FDA has granted BTD for elsunersen, an antisense oligonucleotide for the treatment of seizures associate...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Praxis Precision Medicines, Inc. (PRAX)